KIT and acute myeloid leukemia: CBF-AML are considered leukemias with a highly favorable prognosis although the outcome is highly impacted by the presence of additional genetic mutations, as exemplified by the mutation of FLT3, C-KIT, or NRAS gene [46,47,48,49].